Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy.
OBJECTIVE
To evaluate the treatment outcomes in patients with optimally debulked Stage III and IV endometrial adenocarcinoma (ACA) or Stages I-IV uterine papillary serous (UPSC) or clear cell (CCC) carcinoma of the uterus, treated postoperatively with whole abdominopelvic irradiation (WAPI).


METHODS
Between 1979 and 1998, 48 patients received postoperative WAPI at our institution. Twenty-two patients had FIGO Stage III or Stage IV ACA and 26 patients had FIGO Stages I-IV UPSC or CCC. The median dose was 30 Gy to the upper abdomen and 49.8 Gy to the pelvis. Mean follow-up was 37 months (2.4-135 months).


RESULTS
The 3-year estimated disease-free survival (DFS) and overall survival (OS) rates for the entire group were 60% and 77%, respectively. Patients with ACA had 3-year DFS and OS of 79% and 89%, respectively, compared with 47% and 68% in the UPSC/CCC group. Early-stage patients (I and II) with UPSC/CCC had 3-year DFS and OS of 87% compared with 32% and 61% in those with advanced (Stage III and IV) disease. The 3-year actuarial major complication rate was 7%, with no treatment-related deaths. All 4 failures in the ACA group were extra-abdominal and 6 of the 11 in the UPSC/CCC group had an extra-abdominal component. Age and UPSC/CCC histology were significant prognostic factors for DFS and OS. In addition, stage and number of extrauterine sites of disease were significant predictors for DFS in UPSC/CCC.


CONCLUSIONS
WAPI is a safe, effective treatment for patients with optimally debulked advanced-stage uterine ACA or early-stage UPSC/CCC. Survival was significantly worse in advanced-stage UPSC/CCC patients. We recommend future trials of WAPI with concurrent, or subsequent systemic therapy in patients with advanced-stage UPSC or CCC.
Smith
R S
RS
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Kapp
D S
DS
Chen
Q
Q
Teng
N N
NN
D000005:Abdomen; D018262:Adenocarcinoma, Clear Cell / Q000473:pathology / Q000532:radiotherapy; D000704:Analysis of Variance; D018284:Cystadenocarcinoma, Serous / Q000473:pathology / Q000532:radiotherapy; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D017619:Hemibody Irradiation / Q000379:methods; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010388:Pelvis; D011879:Radiotherapy Dosage; D017211:Treatment Failure; D014594:Uterine Neoplasms / Q000473:pathology / Q000532:radiotherapy*